History of Lung Transplantation.

Turk Thorac J

Department of Chest Surgery, Division of Lung Transplantation, Acıbadem University Atakent Hospital, İstanbul, Turkey.

Published: April 2016

History of lung transplantation in the world can be traced back to the early years of the 20 century when experimental vascular anastomotic techniques were developed by Carrel and Guthrie, followed by transplantation of thoracic organs on animal models by Demikhov and finally it was James Hardy who did the first lung transplantation attempt on human. But it was not until the discovery of cyclosporine and development of better surgical techniques that success could be achieved in that field by the Toronto Lung Transplant Group led by Joel Cooper. Up to the present day, over 51.000 lung transplants were performed in the world at different centers. The start of lung transplantation in Turkey has been delayed for various reasons. From 1998 on, there were several attempts but the first successful lung transplant was performed at Sureyyapasa Hospital in 2009. Today there are four lung transplant centers in Turkey; two in Istanbul, one in Ankara and another one in Izmir. Three lung transplant centers from Istanbul which belong to private sector have newly applied for licence from the Ministry of Health.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5792120PMC
http://dx.doi.org/10.5578/ttj.17.2.014DOI Listing

Publication Analysis

Top Keywords

lung transplantation
16
lung transplant
16
history lung
8
lung
8
transplant centers
8
transplantation
5
transplantation history
4
transplantation traced
4
traced early
4
early years
4

Similar Publications

Xenotransplantation has a rich history, marked by European pioneers who laid the groundwork for many breakthroughs in the field. Pig organ xenotransplantation offers a solution to the global shortage of deceased human donor organs, whilst allowing the modification of the donor graft itself. The field has continued to garner interest, particularly with the recent advent of simpler and faster genetic-engineering technologies.

View Article and Find Full Text PDF

Background: Lung transplantation is the only viable option for end-stage respiratory diseases, with the global prevalence of this procedure on the rise in recent years. However, it is still plagued by various complications, for which no satisfactory therapy has yet been identified. Understanding the mechanisms underlying these post-transplant complications may be beneficial to enhance patient outcomes.

View Article and Find Full Text PDF

New classification and precise prevention strategies for donor lung injury in lung transplantation.

J Thorac Dis

February 2025

State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.

View Article and Find Full Text PDF

COVID-19 caused by the Omicron variant in lung transplant recipients: a single center case series.

J Thorac Dis

February 2025

National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of Medical Sciences, Center of Respiratory Medicine, China-Japan Friendship Hospital, Beijing, China.

Background: Although coronavirus disease 2019 (COVID-19) is no longer classified as a Public Health Emergency of International Concern by World Health Organization, its global impact persists. Data on its impact in lung transplant recipients (LTRs) from China remain limited. This study aims to share clinical experiences and provide insights into managing LTRs with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

View Article and Find Full Text PDF

Background: Pulmonary fibrosis is a severe, progressive form of interstitial lung disease associated with increased morbidity and mortality. Pulmonary hypertension often accompanies severe pulmonary fibrosis and is also associated with worse outcomes. Antifibrotic therapy and pulmonary vasodilator therapy have demonstrated clinical benefits in pulmonary fibrosis and pulmonary hypertension, respectively.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!